Advertisement
Under the terms of the alliance, ASCEND Therapeutics will initiatepromotion of the product in the U.S. in the month of June 2008. ASCEND has a50-person Women's Health sales force which will detail the product primarilyto Obstetricians and Gynecologists (OB/GYNs). Lupin will continue to promotethe product to Pediatricians and Family Practitioners.
Advertisement
The antibiotic market for treatment of Urinary Tract Infections (UTIs) isUSD 450 million, and the OB/GYN area is among the top three physicianspecialties prescribing antibiotics for treatment of UTIs.
"We are pleased to enter into this strategic alliance with ASCEND. Webelieve ASCEND's existing equity with the OB/GYN specialty will help Lupin tofully explore and leverage an additional opportunity for promoting Suprax(R)400 mg Tablets. This alliance reflects Lupin's commitment to building theSuprax(R) franchise and enhancing the value of brand business in the U.S.,"said Vinita Gupta, President, Lupin Pharmaceuticals, Inc.
"We are very excited about adding Suprax(R) 400 mg Tablets to ourportfolio of products which we market to Women's Health professionals," saidJay Bua, President, ASCEND Therapeutics. "There are over 8 million patientvisits for UTIs each year, with the vast majority of these experienced bywomen. Suprax(R) 400 mg Tablets is an established antibiotic with a favorablesafety profile and proven track record in effectively treating UTIs and otherbacterial infections. We very much look forward to a long and productivecollaboration with Lupin."
About Lupin
Lupin Pharmaceuticals, Inc., headquartered in Baltimore, Maryland, is thewholly owned U.S. subsidiary of Mumbai-based Lupin Limited, a leading Indianpharmaceutical company. Lupin Limited develops, manufactures and markets awide range of quality, affordable generic and branded generic formulations andAPIs for both the developed and the developing markets of the world. Twelve ofLupin's facilities have been inspected and approved by the U.S. Food & DrugAdministration.
For the year ended March 2008, Lupin's consolidated revenues and profitafter tax were USD 660.23 million and USD 97.21 million, respectively.
The Company has secured a global leadership position in anti-TB productsand cephalosporins and has a significant presence in the areas ofcardiovasculars (prils and statins), diabetology, asthma and NSAIDs. Currentlypositioned among the top five pharmaceutical companies in India, the Companyis committed to achieving sustainable earnings and growth for all itsstakeholders. For more information, visithttp://www.lupinpharmaceuticals.com.
About ASCEND Therapeutics
ASCEND Therapeutics is a biopharmaceutical company focused on the use oftransdermal drug delivery technology to overcome therapeutic barriers andraise the standard of care for certain chronic conditions. For moreinformation about ASCEND, you may visit the company's web site athttp://www.ascendtherapeutics.com.
Safe Harbor Statement under the U. S. Private Securities Litigation ReformAct of 1995:
This release contains forward-looking statements that involve known andunknown risks, uncertainties and other factors that may cause actual resultsto be materially different from any future results, performance orachievements expressed or implied by such statements. Many of these risks,uncertainties and other factors include failure of clinical trials, delays indevelopment, registration and product approvals, changes in the competitiveenvironment, increased government control over pricing, fluctuations in thecapital and foreign exchange markets and the ability to maintain patent andother intellectual property p
